Bimekizumab
- Generic Name
- Bimekizumab
- Brand Names
- Bimzelx
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1418205-77-2
- Unique Ingredient Identifier
- 09495UIM6V
- Background
Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis. It is the first IL-17 inhibitor to target both IL-17A and IL-17F. It has demonstrated superior efficacy as compared to another IL-17 inhibitor, secukinumab, as well as ustekinumab (an IL-12/23 ...
- Indication
Bimekizumab is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
- Associated Conditions
- Severe Plaque psoriasis, Moderate Plaque psoriasis
- Associated Therapies
- -
Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Centre Hospitalier Universitaire de Nice
- Target Recruit Count
- 40
- Registration Number
- NCT06742333
- Locations
- 🇫🇷
CHU de Nice - Hôpital de l'Archet, Nice, Alpes-Maritimes, France
🇫🇷Hôpital Edouard Herriot, Lyon, France
🇫🇷Hôpital Saint-Joseph, Marseille, France
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 40
- Registration Number
- NCT06668181
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 550
- Registration Number
- NCT06624228
- Locations
- 🇨🇿
Pa0016 40010, Uherske Hradiste, Czechia
🇩🇪Pa0016 40800, Ratingen, Germany
🇭🇺Pa0016 40081, Budapest, Hungary
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 90
- Registration Number
- NCT06506916
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 168
- Registration Number
- NCT06425549
- Locations
- 🇺🇸
Ps0021 50196, Northridge, California, United States
🇺🇸Ps0021 50161, Los Angeles, California, United States
🇺🇸Ps0021 50599, Kew Gardens, New York, United States
Bimekizumab in Plaque Psoriasis
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 60
- Registration Number
- NCT06336343
- Locations
- 🇺🇸
Windsor Dermatology - Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 133
- Registration Number
- NCT06011733
- Locations
- 🇨🇳
Ps0041 20308, Shanghai, China
🇨🇳Ps0041 20117, Guangzhou, China
🇨🇳Ps0041 20310, Ningbo, China
Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Innovaderm Research Inc.
- Registration Number
- NCT05499416
A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 121
- Registration Number
- NCT05292131
- Locations
- 🇺🇸
UP0119 2, Glendale, California, United States
🇩🇪UP0119 1, Berlin, Germany
A Study to Evaluate the Relative Bioavailability and Tolerability of Bimekizumab in Healthy Subjects
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2021-08-31
- Lead Sponsor
- UCB Celltech
- Target Recruit Count
- 12
- Registration Number
- NCT05028127
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.